Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values

Hepatology

Volumn 65, Issue 4, 2017, Pages 1145-1155

  Petta, Salvatore ^a   Wong, Vincent Wai Sun ^b   Cammà, Calogero ^a   Hiriart, Jean Baptiste ^c   Wong, Grace Lai Hung ^b   Marra, Fabio ^d   Vergniol, Julien ^c   Chan, Anthony Wing Hung ^b   Di Marco, Vito ^a   Merrouche, Wassil ^c   Chan, Henry Lik Yuen ^b   Barbara, Marco ^a   Le Bail, Brigitte ^e   Arena, Umberto ^d   Craxì, Antonio ^a   de Ledinghen, Victor ^c,e  

^a UNIVERSITY OF PALERMO   (Italy)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d UNIVERSITY OF FLORENCE   (Italy)

^e HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATTENUATION; AUTOIMMUNE LIVER DISEASE; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTION; SENSITIVITY AND SPECIFICITY; STEATOSIS; TRANSIENT ELASTOGRAPHY; WILSON DISEASE; AGE; AGED; ANALYSIS OF VARIANCE; COHORT ANALYSIS; COMPARATIVE STUDY; ELASTOGRAPHY; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEX DIFFERENCE; TOTAL QUALITY MANAGEMENT; TRENDS;

ADULT; AGE FACTORS; AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; COHORT STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; QUALITY IMPROVEMENT; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 84996503589     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28843     Document Type: Article

References (31)

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 2015;64:73–84.
2. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014;60:110–117.
3. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547–555.
4. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547–1554.
5. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389–397.
6. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898–1906.
7. Petta S, Handberg A, Craxì A. Non invasive indexes for the assessment of patients with non-alcoholic fatty liver disease. Curr Pharm Des 2013;19:5193–5218.
8. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388–1402.
9. Wong VW, Vergniol J, Wong GL, Foucher J, Chan AW, Chermak F, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012;107:1862–1871.
10. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454–462.
11. Cassinotto C, Boursier J, De Ledinghen V, Lebigot J, Lapuyade B, Cales P, et al. Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan and ARFI with liver biopsy. Hepatology 2015;63:1817–1827.
12. Petta S, Maida M, Macaluso FS, Di Marco V, Cammà C, Cabibi D, et al. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology 2015;62:1101–1110.
13. Wong GL, Chan HL, Choi PC, Chan AW, Lo AO, Chim AM, et al. Association between anthropometric parameters and measurements of liver stiffness by transient elastography. Clin Gastroenterol Hepatol 2013;11:295–302.
14. Das K, Sarkar R, Ahmed SM, Mridha AR, Mukherjee PS, Das K, et al. “Normal” liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country. Hepatology 2012;55:584–593.
15. Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011;33:1350–1360.
16. De Lédinghen V, Wong GL, Vergniol J, Chan HL, Hiriart JB, Chan AW, et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016;31:848–855.
17. American Diabetes Association. Clinical practice recommendations 2000. Diabetes Care 2000;23(Suppl.):S4–S19.
18. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al.; Multicentric Group from ANRS/HC/EP23 FIBROSTAR Studies. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57:1182–1191.
19. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239–244.
20. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;411:313–321.
21. Shen F, Zheng RD, Shi JP, Mi YQ, Chen GF, Hu X, et al. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver Int 2015;35:2392–2400.
22. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846–854.
23. Petta S, Vanni E, Bugianesi E, Di Marco V, Cammà C, Cabibi D, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2015;35:1566–1573.
24. Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014;60:1920–1928.
25. Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 2016;150:626–637.
26. Myers RP, Pomier-Layrargues G, Kirsch R, Pollett A, Duarte-Rojo A, Wong D, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012;55:199–208.
27. ®. J Hepatol 2012;56:833–839.
28. Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, et al. Accuracy of FibroScan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 2015;13:772–9.e1-3.
29. Boursier J, Konate A, Guilluy M, Gorea G, Sawadogo A, Quemener E, et al. Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. Eur J Gastroenterol Hepatol 2008;20:693–701.
30. Recio E, Cifuentes C, Macías J, Mira JA, Parra-Sánchez M, Rivero-Juárez A, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol 2013;25:905–911.
31. Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E, et al. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. J Hepatol 2016;64:682–690.